Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Status: Completed

Protocol number: ML19199

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A study to investigate the impact of pharmacogenetics on CellCept use, in patients participating in a study in renal transplantation

Brief summary: This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic outcomes observed with CellCept usage. Patients participating in study ML17225 will be eligible for this pharmacogenetic investigation, and will have one additional blood sample taken during the study. The anticipated time on study treatment in study ML17225 is 1-2 years, and the target sample size is 500+ individuals. Target sample size is 300.

Study phase: IV

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Kidney Transplantation

Intervention type: Drug

Intervention name: mycophenolate mofetil [CellCept]

Primary outcome: 1. Correlation of allelic variants of MPA metabolizing genes, membrane transporter genes and target genes with AUC, transplant rejection, GER and drug side effects. Time frame: Throughout study

Key secondary outcomes: 1. Viral kinetics Time frame: Throughout study

Inclusion criteria:

  • patients participating in study ML17225.

Exclusion criteria:

  • N/A.

Gender: Males or Females

Age limits: Min: 13 Years Max: 75 Years

Accepts healthy volunteers: No

Trial registration date: 06/16/2006

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

United States

  • Little Rock, AR
  • Los Angeles, CA
  • Denver, CO
  • Gainesville, FL
  • Orlando, FL
  • Chicago, IL
  • Indianapolis , IN
  • Lexington, KY
  • Boston, MA
  • Hackensack, NJ
  • Livingston, NJ
  • Buffalo, NY
  • Chapel Hill, NC
  • Fargo, ND
  • Portland, OR
  • Philadelphia, PA
  • Madison, WI

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply

© 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement